美国食品药品监督管理局的透明度承诺。

FDA's commitment to transparency.

机构信息

Department of Pharmacy Baptist Health Montgomery, AL.

University of Massachusetts Medical School Montgomery, AL.

出版信息

Am J Health Syst Pharm. 2021 Aug 30;78(17):1550-1551. doi: 10.1093/ajhp/zxab053.

DOI:10.1093/ajhp/zxab053

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7929384/

Abstract

In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

摘要

为了加快与 COVID-19 大流行相关文章的出版，AJHP 在接受后尽快将这些手稿在线发布。已接受的手稿已经经过同行评审和编辑，但在进行技术格式设置和作者校对之前在线发布。这些手稿不是最终记录版本，稍后将用最终文章（按照 AJHP 风格格式化并由作者校对）替换。

相似文献

1

FDA's commitment to transparency.美国食品药品监督管理局的透明度承诺。

Am J Health Syst Pharm. 2021 Aug 30;78(17):1550-1551. doi: 10.1093/ajhp/zxab053.

2

Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.根据联邦《食品、药品和化妆品法案》进行的药品和医疗器械出口：谢尔希案后美国食品药品监督管理局在解释上的显著变化。

Food Drug Law J. 2009;64(1):149-69.

3

FDA's decision on Plan B: a surrogate for lack of commitment to women's health.美国食品药品监督管理局对“紧急避孕药”的决定：是对女性健康缺乏关注的一种表现。

J Womens Health (Larchmt). 2005 Nov;14(9):860. doi: 10.1089/jwh.2005.14.860.

4

FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.美国食品药品监督管理局扩大上市后监管权限以监测并公布食品及消费品健康风险：在9·11后的监管环境中，需要程序保障措施来减少“透明度”政策带来的危害

Food Drug Law J. 2009;64(3):577-98.

5

FDA's post-approval studies continue to suffer delays and setbacks.美国食品药品监督管理局（FDA）批准后的研究仍在持续遭遇延误和挫折。

Nat Med. 2014 Nov;20(11):1224-5. doi: 10.1038/nm1114-1224.

6

Accelerated Approval - Taking the FDA's Concerns Seriously.加速批准——认真对待美国食品药品监督管理局的担忧。

N Engl J Med. 2022 Jul 21;387(3):199-201. doi: 10.1056/NEJMp2204487. Epub 2022 Jul 6.

7

The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.肿瘤药物咨询委员会纪事：第3部分。美国食品药品监督管理局评估和批准癌症药物的理念与流程。

Expert Rev Anticancer Ther. 2005 Feb;5(1):1-5. doi: 10.1586/14737140.5.1.1.

8

What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help.戈特利布专员领导的美国食品药品监督管理局（FDA）为降低处方药价格所采取的措施以及国会可采取的协助措施。

Issue Brief (Commonw Fund). 2018 Apr 1;2018:1-10.

9

The FDA's definitions, designations, and drug approvals: too daring?美国食品药品监督管理局的定义、指定和药物批准：是否过于大胆？

Lancet Haematol. 2018 Aug;5(8):e321. doi: 10.1016/S2352-3026(18)30115-7.

10

FDA's Flexibility in Subpart H Approvals: Assessing Quantum of Effectiveness Evidence.美国食品药品监督管理局在H子部分审批中的灵活性：评估有效性证据的数量

Food Drug Law J. 2016 Aug;71(1):135-157.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验